Evogene Ltd. (EVGN) company profile

Evogene Ltd. is a computational biology company that develops products for life science markets. The company operates through specialized subsidiaries focused on agriculture, human health, and industrial applications, including AgPlenus, Biomica, Casterra Ag, and Lavie Bio. Evogene's offerings encompass agricultural biologicals, microbiome-based therapeutics, ag-chemicals, and castor seed solutions, addressing the needs of agricultural producers, industrial partners, and healthcare entities.

The company conducts business activities across international markets, with operations and collaborations spanning the United States, Israel, Europe, and Africa. Evogene maintains research and development facilities comprising specialized laboratory spaces and office facilities. Evogene Ltd. is incorporated in Israel and maintains its principal executive offices in Rehovot, Israel.

Summary of the business section of Evogene's latest annual report, written by StockData.

“Per Share Total Public offering price $14.750 $73,750,000 Underwriting discounts and commissions(1)(2) $ 1.033 $ 4,322,499 Proceeds to us (before expenses) $13.717 $69,427,501 (1) See “Underwriting” for a description of the compensation payable to the underwriters.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“The Companies Law codifies the fiduciary duties that office holders owe to a company. Many of the executive officers listed in the table under “Item 6. Directors, Senior Management and Employees— … 78”